A group of researchers from TUSKEEGEE UNIVERSITY have developed a new testing method to detect the most aggressive and fatal form of BREAST CANCER in BLACK WOMEN.
The research findings at the legendary HBCU have uncovered a fourth biological testing marker that is used to subtype Breast Cancer, and could offer a breakthrough in Breast Cancer Early Detection and more precise methods of treatment.
VIBE Magazine reports;
A total of 1258 patients were analyzed for the study which assessed androgen receptor (AR) and mRNA expression in 925 tumors from The Cancer Genome Atlas (TCGA), as well as 136 tumors in two confirmation sets, in addition to determining AR protein expression in 171 tumors from a “multi-institutional cohort.” The findings determined that androgen receptors could be used as a prognostic marker for breast cancer, particularly in triple and quadruple negative breast cancers, or tumors that “lack AR expression,” as detailed in a report published last week in peer-reviewed medical journal PLOS ONE.
Statistically, AR-negative patients are diagnosed at a younger age, while the average age of AR-positive patients is 49. According to the study, tumors in black patients express AR at lower rates in comparisons to white women. Black women are more likely to be diagnosed with triple negative breast cancer (a more aggressive type of breast cancer) at a younger age.
Dr. CLAYTON YATES is director for the TUSKEEGEE MULTIDISCIPLINARY CENTER For BIOMEDICAL RESEARCH.
Dr. CLAYTON YATES stated;
“Scientifically speaking, our research suggests that the expression of the androgen receptor (the receptor for testosterone), should be added to the current set of prognostic markers — estrogen, progesterone and human epidermal growth factor receptor [two] — used to test for classify and determine the aggressiveness of breast cancer,”
“As with any fight, you have to know your enemy,” he added. “Imagine going into battle not knowing if you needed a BB gun, a shotgun,or a bazooka. With this additional testing option, physicians will be able to better define the enemy and develop a more precise treatment plan. This, in turn, promises to be more effective for the patient — not to mention safer and less expensive — in the long run.”
TUSKEEGEE UNIVERSITY NEWS reports the team is led by TUSKEEGEE Assistant Research Professor Dr. SHWETA TRIPATHI and Department of Biology & Center for Cancer Research Master's Student RAYMOND HUGELY.
They are working in collaboration with breast cancer research specialists HENRY FORD HEALTH SYSTEM Genetics Professor Dr. MELISSA DAVIS and HENRY FORD CANCER INSTITUTE BREAST ONCOLOGY PROGRAM Director/ INTERNATIONAL CENTER For The STUDY Of BREAST CANCER SUBTYPES Medical Director Dr. LISA NEWMAN.
MEDICAL ONCOLOGIST Dr. WINDY DEAN-HOLOMB is medical director of St. Patrick CHRIST'S Hospital in Lake Charles, LA.
Dr. WINDY DEAN HOLOMB stated;
“The addition of androgen receptor as a fourth biomarker could be game-changing, in not only how we treat all patients with TNBC (triple negative breast cancer), but really sets the foundation for this unique subtype called QNBC (quadruple negative breast cancer)."
Dr. YATES stated:
“Study after study proves that early detection is the key to long-term survival,” Yates said. “Our new testing method shows significant promise for as a prognostic marker for the most aggressive types of breast cancer — African-American women that lack AR expression are diagnosed 10 years earlier than patients with positive AR expression."
Read the full report on TUDKEEGEE UNIVERSITY RESEARCHERS Developing NEW TESTING METHOD For EARLY DETECTION Of AGGRESSINE BREAST CANCER In BLACK WOMEN.
HAPPY TAKE OFF YOUR BRA, TAKE CARE Of YOUR BREASTS And NIPPLES, And; TAKE CARE Of YOURSELVES EARLY BREAST CANCER DETECTION BRALESS THURSDAY!!!
PEACE, LOVE, And; BEAUTIFUL BOUNTIFUL BRALESS THURSDAY BLESSINGS;